JHL Biotech Raises $45.6 Million in C Round

JHL Biotech, a Taiwan-China biopharma, closed a Series C round of $45.6 million. The company said the funding would be the last before it stages an IPO in Taiwan. JHL also has a manufacturing facility in Wuhan, China to support China-for-China biosimilar development. With the new capital in hand, JHL says it has enough money to complete full development and BLA filing of at least two of its proprietary biosimilar drugs. More details.... Share this with colleagues: // //